Docs Applaud Supreme Court Upholding Mifepristone Access
Physician groups and clinicians on social media expressed relief at the Supreme Court decision upholding the broad availability of the abortion drug.
Source: medscape.com
Page 2 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Risk Evaluation Today - Breaking & Trending Today
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
Source: ajmc.com
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma ...
Source: pharmiweb.com
FDA Approves Bkemv, an Interchangeable Biosimilar to Soliris
The approval was supported by data from the double-blind, active-controlled, 2-period crossover, phase 3 DAHLIA study.
Source: empr.com
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Source: finanznachrichten.de